Abstract library

45 results for "Degli Uberti".
#265 A Novel PKCßII Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells
Introduction: Deregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Chiara Zatelli
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli
#425 Successful Treatment with Everolimus of Functioning Liver Metastases From a Pancreatic Insulinoma
Introduction: Medical treatment of metastatic insulinoma is debated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Maria Chiara Zatelli
#429 Bronchial Carcinoid Response to mTOR Inhibitors Depends on mTOR Expression Levels
Introduction: Bronchial carcinoids (BCs), originating from endocrine cells dispersed in the respiratory epithelium, can be divided into typical (TBC) and atypical (ABC). TBC are less aggressive, smaller, and much less likely to metastasize, while ABC are more aggressive and metastasize. mTOR has a central role in regulating cell growth, metabolism, and apoptosis. A differential mTOR activation in BCs has been previously demonstrated, suggesting that mTOR pathway might play a predictive role in patients eligible for mTOR-targeted therapies
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Teresa Gagliano
Keywords: BC, mTOR
#430 mTOR Inhibitors Hamper Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that mTOR inhibitors have potent anti-proliferative effects in a human Medullary Thyroid Carcinoma (MTC) cell line. We here explore the possible role of mTOR inhibitors, Everolimus and BEZ235 (which also inhibits the PI3K pathway) on the effects of Insulin-like Growth Factor-1 (IGF-1) in human MTC primary cultures.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mrs. Mariella Minoia
#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Maria Rosaria Ambrosio
#680 Role of EGF Pathway in Regulating Bronchial Carcinoid Cell Proliferation
Introduction: Bronchial carcinoids (BC) are rare neuroendocrine tumors. Surgery is not feasible for infiltrating and metastatic disease. Medical therapy is often tried but is represented by chemotherapy and radiation, while somatostatin analogues are employed for symptomatic control. It is necessary to identify new molecules capable of providing medical treatment in cases for which surgical removal is not feasible. EGF, TGFα are growth factors which were demonstrated to be important in neuroendocrine tumors. EGF and TGFα bind to the EGF receptor and lead to the transcription of genes that regulate cell proliferation.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: EGF, EGFR, BC
#933 The Cytotoxic Effect of Sunitinib on Human Bronchial Carcinoid Cell Lines and Primary Cultures is Counteracted by EGF and IGF-1, but not by VEGF
Introduction: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, but which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: BC, RTK, Sunitinib
#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors
Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Francesco Panzuto
#962 Cyclin D1 Levels are Involved in the Resistance to m-TOR Inhibitors in Human Bronchial Carcinoids
Introduction: Bronchial carcinoids (BC) are still orphans of medical therapy. We previously demonstrated that the typical BC human cell line NCI-H727 is sensitive to Everolimus, in terms of cell viability reduction, while the atypical human BC cell line NCI-H720 is not. However, the mechanisms underlying this phenomenon have not been fully clarified.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Master degree Katiuscia Benfini
Keywords: BC, mTOR